Get started
Author

Robert Sverdlin

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
2023 · Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, et al. · Journal of Clinical Oncology · 116
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer
2021 · Claire Falandry, Frédérique Rousseau, et al. · JAMA Oncology · 81
PDF
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al. · Clinical Cancer Research · 34
PDF
Docetaxel–cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer
1999 · M. Spielmann, A. Llombart, et al. · Annals of Oncology · 34
PDF
EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.
2019 · Claire Falandry, Aude Marie Savoye, et al. · Journal of Clinical Oncology · 26
18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial
2020 · P. Harter, D. Petran, et al. · International Journal of Gynecological Cancer · 11
PDF
812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial
2020 · N. Colombo, J. Gantzer, et al. · Annals of Oncology · 4
Chronomodulated irinotecan (I), fluorouracil (F), leucovorin (L), and oxaliplatin (O) (chrono IFLO) as salvage therapy in oxaliplatin- and irinotecan-resistant advanced colorectal cancer (ACRC): Treatment results and toxicity profile
2004 · D. Gholam, S. Giacchetti, et al. · Journal of Clinical Oncology · 1
Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
PDF
Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Figure S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
PDF
Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer
2024 · Emeric Boisteau, Laetitia Dahan, et al. · The Oncologist
PDF
Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al.
Works count: 40
Citation count: 307
H-index: 6
I10-index: 6
Year
Topic
Type